Chronic drug intake has been associated with negative and positive cognitive effects in elderly people, although subjacent conditions may be confounding factors.
Aim:
To study the effects on cognitive performance of commonly prescribed medications in a cohort of cognitively normal older adults.
Methods:
Medication intake was recorded during two years in 1087 individuals 70–85 years old, without neurological or psychiatric conditions. The influence of every drug, drug family and therapeutic group on six cognitive scores and on the conversion to mild cognitive impairment over two years was ascertained by cross-sectional and longitudinal analyses controlling for demographic and clinical variables.
Results:
Small effects of several drugs on information processing were found in cross-sectional analyses but only confirmed for a positive effect of vitamin D in case–control analyses. Longitudinal analyses showed no drug effects on the cognitive slopes. Several hypotensive drugs reduced, whereas bromazepam and glucose lowering drugs increased, the conversion rate to mild cognitive impairment with very small effects (R2=0.3–1%).
Conclusions:
Cognitively healthy elderly individuals show minimal negative effects on information processing associated with chronic intake of some drugs probably related to the subjacent condition. Some drugs slightly affect the rate of conversion to mild cognitive impairment. Positive effects of vitamin D, chondroitin, atorvastatin and antihypertensive drugs, and negative effects of antidepressants and benzodiazepines, should be further explored in studies with longer follow-up.
AncelinMLArteroSPortetFet al. (2006) Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: Longitudinal cohort study. Br Med J332: 455–459.
2.
AnnweilerCDursunEFéronFet al. (2015) ‘Vitamin D and cognition in older adults’: Updated international recommendations. J Intern Med277: 45–57.
3.
BeaudreauSAO’HaraR (2009) The association of anxiety and depressive symptoms with cognitive performance in community-dwelling older adults. Psychol Aging24: 507–512.
4.
Benito-LeónJLouisEDVegaSet al. (2010) Statins and cognitive functioning in the elderly: A population-based study. J Alzheimers Dis21: 95–102.
5.
BilliotideGageSMorideYDucruetTet al. (2014) Benzodiazepine use and risk of Alzheimer’s disease: Case–control study. Br Med J349: g5205.
6.
BolkerBMBrooksMEClarkCJet al. (2009) Generalized linear mixed models: A practical guide for ecology and evolution. Trends Ecol Evol24: 127–135.
7.
BourgeoisJElseviersMMVan BortelLet al. (2015) The impact of chronic benzodiazepine use on cognitive evolution in nursing home residents. Hum Psychopharmacol30: 85–93.
8.
Brouwer-BrolsmaEMde GrootLC (2015) Vitamin D and cognition in older adults: An update of recent findings. Curr Opin Clin Nutr Metab Care18: 11–16.
9.
CampbellJMStephensonMDde CourtenBet al. (2018) Metformin use associated with reduced risk of dementia in patients with diabetes: A systematic review and meta-analysis. J Alzheimers Dis65: 1225–1236.
10.
CherbuinNReglade-MeslinCKumarRet al. (2009) Risk factors of transition from normal cognition to mild cognitive disorder: The PATH through Life Study. Dement Geriatr Cogn Dis Extra28: 47–55.
11.
ChuangCSLinCLLinMCet al. (2015) Decreased prevalence of dementia associated with statins: A national population-based study. Eur J Neurol22: 912–918.
12.
CraftSBakerLDMontineTJet al. (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol69: 29–38.
13.
Cruz GuerraNAPerales CéspedesMP (2005) Cognitive and behavioural alterations as adverse reaction to tamsulosin not previously described. Arch Esp Urol58: 69–71.
14.
DetreJAWolkDAArnoldSE (2017) Effects of the insulin sensitizer metformin in Alzheimer disease: Pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disord31: 107–113.
15.
DublinSWalkerRLGraySLet al. (2015) Prescription opioids and risk of dementia or cognitive decline: A prospective cohort study. J Am Geriatr Soc63: 1519–1526.
16.
GaultVALennoxRFlattPR (2015) Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes Metab17: 403–413.
17.
HajjarIBrownLMackWJet al. (2012) Impact of angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series. Arch Neurol69: 1632–1638.
18.
HsuCCWahlqvistMLLeeMSet al. (2011) Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis24: 485–493.
19.
HwangIKKimIYJooEJet al. (2010) Metformin normalizes type 2 diabetes-induced decrease in cell proliferation and neuroblast differentiation in the rat dentate gyrus. Neurochem Res35: 645–650.
20.
JoostenHVisserSTVan EerselMEet al. (2014) Statin use and cognitive function: Population-based observational study with long-term follow-up. PLoS One9: e115755.
21.
KuanYCHuangKWLinCLet al. (2017) Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry79: 77–83.
22.
LandelVAnnweilerCMilletPet al. (2016) Vitamin D, cognition and Alzheimer’s disease: The therapeutic benefit is in the D-tails. J Alzheimers Dis53: 419–444.
23.
Levi-MarpillatNMacquin-MavierITropeanoA-Iet al. (2013) Antihypertensive classes, cognitive decline and incidence of dementia. J Hypertens31: 1073–1082.
24.
LillySMMortensenEMFreiCRet al. (2014) Comparison of the risk of psychological and cognitive disorders between persistent and nonpersistent statin users. Am J Cardiol114: 1035–1039.
25.
LuchsingerJAPerezTChangHet al. (2016) Metformin in amnestic mild cognitive impairment: Results of a pilot randomized placebo controlled clinical trial. J Alzheimers Dis51: 501–514.
26.
MandasACongiuMGAbeteCet al. (2014) Cognitive decline and depressive symptoms in late-life are associated with statin use: Evidence from a population-based study of Sardinian old people living in their own home. Neurol Res36: 247–254.
27.
MooreEMManderAGAmesDet al. (2013) Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care36: 2981–2987
28.
MuraTProust-LimaCAkbaralyTet al. (2013) Chronic use of benzodiazepines and latent cognitive decline in the elderly: Results from the three-city study. Eur Neuropsychopharmacol23: 212–223.
29.
NebesRDPollockBGPereraSet al. (2012) The greater sensitivity of elderly APOE E4 carriers to anticholinergic medications is independent of cerebrovascular disease risk. Am J Geriatr Pharmacother20: 185–192.
30.
Nevado-HolgadoAJKimCHWinchesterLet al. (2016) Commonly prescribed drugs associate with cognitive function: A cross-sectional study in UK Biobank. BMJ Open6: e012177.
31.
NgTPFengLYapKBet al. (2014) Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis41: 61–68.
32.
ObermannKRMorrisJCRoeCM (2013) Exploration of 100 commonly used drugs and supplements on cognition in older adults. Alzheimers Dement9: 724–732.
33.
OlazaránJValentíMFradesBet al. (2015) Identifying early markers and mechanisms in Alzheimer’s disease: Methods and inclusion results of the Vallecas Project. Front Aging Neurosci7: 181.
34.
OttBRDaielloLADahabrehIJet al. (2015) Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med30: 348–358.
35.
PaternitiSDufouilCAlpérovitchA (2002) Long-term benzodiazepine use and cognitive decline in the elderly: The Epidemiology of Vascular Aging Study. J Clin Psychopharmacol22: 285–293.
36.
PowerRCoenRFBeattySet al. (2018) Supplemental retinal carotenoids enhance memory in healthy individuals with low levels of macular pigment in a randomized, double-blind, placebo-controlled clinical trial. J Alzheimers Dis61: 947–961.
37.
PuustinenJNurminenJLöppönenMet al. (2011) Use of CNS medications and cognitive decline in the aged: A longitudinal population-based study. BMC Geriatr11: 70.
38.
RaumHDietscheBNagelsAet al. (2015) A genome-wide supported psychiatric risk variant in NCAN influences brain function and cognitive performance in healthy subjects. Hum Brain Mapp36: 378–90.
39.
RisacherSLMcDonaldBCTallmanEFet al. (2016) Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol73: 721–732.
40.
RozziniLChiloviBVBertolettiEet al. (2006) Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry21: 550–555.
41.
SmithKBKangPSabbaghMNet al. (2017) The effect of statins on rate of cognitive decline in mild cognitive impairment. Alzheimers Dement3: 149–156.
42.
SolfrizziVScafatoEFrisardiVet al. (2013) Italian Longitudinal Study on Aging Working Group. Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age35: 441–453.
43.
SonSMShinHJByunJet al. (2016) Metformin facilitates amyloid-β generation by β- and γ-secretases via autophagy activation. J Alzheimers Dis51: 1197–1208.
44.
SteenlandKZhaoLGoldsteinFCet al. (2013) Statins and cognitive decline in older adults with normal cognition or mild cognitive impairment. J Am Geriatr Soc61: 1449–1455.
45.
TrompetSvan VlietPde CraenAJet al. (2010) Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol257: 85–90.
46.
WinbladBPalmerKKivipeltoMet al. (2004) Mild cognitive impairment – beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med256: 240–246.
47.
WrightRMRoumaniYFBoudreauRet al. (2009) Effect of central nervous system medication use on decline in cognition in community-dwelling older adults: Findings from the Health, Aging and Body Composition Study. J Am Geriatr Soc57: 243–250.
48.
XuGBaiFLinXet al. (2017) Association between antihypertensive drug use and the incidence of cognitive decline and dementia: A meta-analysis of prospective cohort studies. Biomed Res Int2017: 4368474.
49.
YasarSXiaJYaoWet al. (2013) Ginkgo Evaluation of Memory (GEM) Study Investigators. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology81: 896–903.
50.
ZhangYZhouXHMeranusDH (2016) Benzodiazepine use and cognitive decline in elderly with normal cognition. Alzheimer Dis Assoc Disord30: 113–117.
51.
ZhongGCWangYZhangYet al. (2015) Association between benzodiazepine use and dementia: A meta- analysis. PLoS One10: e0127836.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
